Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy

Resectable Pancreatic Ductal Adenocarcinoma Clinical Trial

— RADAR-PANC  

Official title:

Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy: a Nationwide Randomized Controlled Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04875325
• Other study ID #: NL67115.041.18
• Secondary ID: 20-762
• Status: Enrolling by invitation
• Phase: N/A
• Start date: March 16, 2021
• Est. completion date: March 2024

Study information

• Verified date: May 2022
• Source: UMC Utrecht
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of a standardized surveillance, with serial tumor marker testing and routine imaging, compared to current non-standardized practice, on overall survival and quality of life in patients with primary resected PDAC is investigated. The most important secondary endpoint is quality of life. Other secondary endpoints are clinical and radiological patterns of PDAC recurrence, the compliance of patients to our standardized follow-up strategy, the impact of a standardized surveillance on (eligibility for) additional treatment, and the tolerance of additional treatment. The need for this clinical trial is emphasized by the the emergence of more potent local and more effective systemic treatments for PDAC recurrence, leading to a rising interest in early diagnosis by a standardized approach to follow-up with routine imaging and serial serum tumor marker testing.

Description:

Rationale: Radical resection combined with (neo)adjuvant chemotherapy offers the best chances for long-term survival for patients with resectable localized pancreatic ductal adenocarcinoma (PDAC). However, even after radical resection, almost all patients will experience local and/or distant disease recurrence after sufficient follow-up, mostly within 2 years. There is a lack of evidence based effective therapeutic options for the significant group of patients with local recurrence only, in terms of improved survival and/or quality of life. In the case of metastatic disease effective chemotherapy has shown to improve survival, but with a median gain survival of 3-4 months. Taken together, this had led to a hesitant attitude towards postoperative recurrence-focused follow-up. Therefore, in most European countries, including the Netherlands, a standardized approach to follow-up after surgery for PDAC is lacking. Furthermore, current PDAC guidelines regarding follow-up are based on expert opinion and other low-level evidence. However, the emergence of more potent local and more effective systemic treatments for PDAC has led to a rising interest in early diagnosis of PDAC recurrence. To detect PDAC recurrence at an early stage and identify patients with good performance status who are most likely to benefit from additional (experimental) treatment, a standardized approach to follow-up with routine imaging and serial serum tumor marker testing is needed. To determine whether early detection of recurrence can lead to improved survival and quality of life, further studies are warranted.

Objective: The main objective is to evaluate the impact of a standardized surveillance, with serial tumor marker testing and routine imaging, on overall survival and quality of life in patients with primary resected PDAC, compared to current non-standardized practice.

Study design: A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design.

Study population: PACAP-participants with histologically confirmed radical resection (R0-R1) of PDAC, who provided informed consent for being randomized in future studies.

Interventions: Standardized surveillance, existing of clinical evaluation, serum cancer antigen (CA) 19-9 testing, and contrast-enhanced computed tomography (CT-) imaging of chest and abdomen every 3 months during the first 2 years after surgery.

Comparison: Non-standardized clinical follow-up.

Endpoints: The main study endpoint is overall survival. The most important secondary endpoint is quality of life. Other secondary endpoints are clinical and radiological patterns of PDAC recurrence, the compliance of patients to our standardized follow-up strategy, the impact of a standardized surveillance on (eligibility for) additional treatment, and the tolerance of additional treatment.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 202
• Est. completion date: March 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Participation in the PACAP cohort with written informed consent for being randomized in future studies

• Histologically confirmed macroscopically radical resected (R0-R1) pancreatic adenocarcinoma

• Minimum age of 18 years

Exclusion Criteria:

• Exclusion criteria for contrast-enhanced CT-scan, following the protocol of the department of radiology in each DPCG-affiliated hospital

• Mentally or physically incapable of consent

• Participation in other studies with a study-specific follow-up

Related Conditions & MeSH terms

• Adenocarcinoma
• Resectable Pancreatic Ductal Adenocarcinoma

Intervention

Other:
• Standardized surveillance
Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.

Locations

Country	Name	City	State
Netherlands	Amsterdam University Medical Center AMC	Amsterdam	Noord-Holland
Netherlands	Amsterdam University Medical Center VUmc	Amsterdam	Noord-Holland
Netherlands	Onze Lieve Vrouwe Gasthuis	Amsterdam	Noord-Holland
Netherlands	Catharina Ziekenhuis	Eindhoven	Noord-Brabant
Netherlands	Medisch Spectrum Twente	Enschede	Overijssel
Netherlands	University Medical Center Groningen	Groningen
Netherlands	Sint Antonius Ziekenhuis	Nieuwegein	Utrecht
Netherlands	Radboud University Medical Center	Nijmegen	Gelderland
Netherlands	University Medical Center Utrecht	Utrecht

Sponsors (2)

Lead Sponsor	Collaborator
UMC Utrecht	Dutch Pancreatic Cancer Group (DPCG)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Clinical patterns of disease recurrence assessed by the patients symptoms as reported in the electronic patient dossier: explanatory		From date of randomization until disease recurrence or last follow-up, assessed up to 24 months
Other	Clinical patterns of disease recurrence assessed by physicial examination as reported in the electronic patient dossier: explanatory		From date of randomization until disease recurrence or last follow-up, assessed up to 24 months
Other	Clinical patterns of disease recurrence assessed by blood test results as reported in the electronic patient dossier: explanatory		From date of randomization until disease recurrence or last follow-up, assessed up to 24 months
Other	Radiological patterns of disease recurrence assessed by information from imaging reports from the electronic patient dossier: explanatory		From date of randomization until disease recurrence or last follow-up, assessed up to 24 months
Primary	Overall survival	The interval between the date of PDAC resection and either death from any cause or last follow-up.	From date of PDAC resection until date of death from any cause or date of last follow-up, whichever came first, assessed up to 24 months
Secondary	Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire	Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.	At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 24 months
Secondary	Patient reported non-disease specific health-related Quality of Life (HRQoL) as assessed using the EQ-5D-5L	Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.	At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 24 months
Secondary	Patient reported cancer-specific HRQoL as assessed using the EORTC QLQ-C30	Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.	At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 24 months
Secondary	Patient reported tumor-specific HRQoL as assessed using the EORTC LQPAN26	Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.	At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 24 months
Secondary	Patient reported chemotherapy-induced peripheral neuropathy as assessed using the EORTC QLQ-CIPN20	Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.	At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 24 months
Secondary	Patient reported Quality of Life as assessed using the happiness, hospital, anxiety and depression scale (HADS)	Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.	At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 24 months
Secondary	Patient reported Quality of Life as assessed using the worry of progression of cancer scale (WOPS)	Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.	At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 24 months
Secondary	Compliance of the standardized surveillance strategy	The percentage of patients that either accepts or refuses participation in the intervention-arm, i.e. is willing to undergo a standardized follow-up regime.	Through completion of patient inclusion, an average of 1.5 years
Secondary	Recurrence-free interval	The interval between the date of PDAC resection and the date of first radiological signs of recurrence, or last follow-up if recurrence is not observed.	From date of PDAC resection until date of first radiological signs of recurrence, or last follow-up if recurrence is not observed, whichever came first, assessed up to 24 months
Secondary	Prognostic patient specific characteristics and tumor related factors for disease recurrence		From date of randomization until disease recurrence or last follow-up, assessed up to 24 months
Secondary	Role of serum tumor marker testing in detecting recurrent PDAC assessed by the calculated diagnostic accuracy values		From date of randomization until disease recurrence or last follow-up, assessed up to 24 months
Secondary	Eligibility for additional (experimental) treatment at the time of recurrence diagnosis based on the ECOG or Karnofsky performance state, or inclusion criteria for study-related treatment of recurrence		At the time of recurrence diagnosis. Assessed through the study, up to 24 months
Secondary	Reasons to refrain from treatment for recurrence	e.g. poor condition, patients wish, deteriorated condition, progressive disease, advise treating clinician, death, wait-and-see, age.	At the time the patient is assessed eligible for additional treatment. Assessed through the study, up to 24 months
Secondary	Patients' tolerance of additional treatment for PDAC recurrence as assessed by incidence of adverse events (graded according to NCI CTCAE Version 5.0)		Through study completion, an average of 2 years
Secondary	Morbidity associated with diagnostic testing assessed by the side-effects of diagnostic testing (i.e. fear of disease recurrence)		From date of randomization until disease recurrence or last follow-up, whichever came first, assessed up to 24 months
Secondary	Overall costs of a standardized surveillance strategy versus the costs as incurred with the current non-standardized follow-up assessed according to the EQ-5D questionnaire as part of the PACAP-project, and calculated using to a Markov model		After study completion (estimated duration of 3.5 years)